stockrowPetMed Express, Inc.
PETS Healthcare Pharmaceutical Retailers
PetMed Express, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $179.0 million, down 21.1% from fiscal 2025.
- Revenue
- −19.9%
- EPS
- +83.0%
- Free cash flow
- +38.6%
Quarter to June 2026, against a year earlier
Follow PETS
Alert me
PetMed Express, Inc. (PETS) EV/Sales
As of 6 November 2026, PetMed Express, Inc. (PETS) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from 0.0× (December 2025) to 3.7× (July 2017); the current reading is higher than 3% of that period. That is below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.1× | 5.54% |
| FY2025 | 0.1× | (5.05%) |
| FY2024 | 0.1× | (83.89%) |
| FY2023 | 0.9× | (39.51%) |
| FY2022 | 1.5× | (22.22%) |
| FY2021 | 1.9× | 16.14% |
| FY2020 | 1.7× | 26.66% |
| FY2019 | 1.3× | (52.69%) |
| FY2018 | 2.8× | 98.51% |
| FY2017 | 1.4× | 1.76% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.2× | 15.19% |
| Mar 2026 | 0.1× | (31.91%) |
| Dec 2025 | 0.2× | 161.65% |
| Sep 2025 | 0.1× | (37.15%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDGT Ridgetech Inc. compare | 0.0× |
| POM Pomdoctor Limited - Sponsored ADR compare | n/m |
| PETS PetMed Express, Inc. | 0.1× |
| HITI High Tide Inc. compare | 0.5× |
| SCNX Scienture Holdings, Inc. compare | 8.4× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)